{
    "Clinical Trial ID": "NCT00334802",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Dose Level 1",
        "  Gemcitabine: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles",
        "INTERVENTION 2: ",
        "  Dose Level 2",
        "  Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically and/or cytologically confirmed breast cancer",
        "  Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen",
        "  To have at least one measurable region",
        "  Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1",
        "  To have adequate organ function (bone marrow, liver and renal function)",
        "Exclusion Criteria:",
        "  To have interstitial pneumonia or pulmonary fibrosis",
        "  To have inflammatory breast cancer",
        "  Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery",
        "  To have brain metastases with symptoms",
        "  To have severe complication (cardiac infarction, infection, drug hypersensitivity or diabetes)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Tumor Response",
        "  Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatment. Responders are patients with complete response or partial response.",
        "  Time frame: baseline to measured progressive disease",
        "Results 1: ",
        "  Arm/Group Title: Dose Level 1",
        "  Arm/Group Description: Gemcitabine: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response: 0",
        "  Partial Response: 3",
        "  Stable Disease: 1",
        "  Progressive Disease: 1",
        "Not Evaluable: 1",
        "Results 2: ",
        "  Arm/Group Title: Dose Level 2",
        "  Arm/Group Description: Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles",
        "  Overall Number of Participants Analyzed: 56",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response: 0",
        "  Partial Response: 25",
        "  Stable Disease: 17",
        "  Progressive Disease: 11",
        "Not Evaluable: 3"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1",
        "  Pneumonia 0/6 (0.00%)",
        "  Haemoglobin decreased 1/6 (16.67%)",
        "  Anorexia 0/6 (0.00%)",
        "  Panic disorder 0/6 (0.00%)",
        "Adverse Events 2:",
        "  Total: 3",
        "  Pneumonia 1/56 (1.79%)",
        "  Haemoglobin decreased 0/56 (0.00%)",
        "  Anorexia 1/56 (1.79%)",
        "  Panic disorder 1/56 (1.79%)"
    ]
}